Evidence map›Paper›PMID 28491264›Full record

ArticleTherapeutic advances in hematology2017

Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma.

Yazan Abuodeh, Kamran Ahmed, Michelle Echevarria, Arash Naghavi, G Daniel Grass, Timothy J Robinson, Michael Tomblyn, Bijal Shah, Julio Chavez, Celeste Bello and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Yazan AbuodehDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Kamran AhmedDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Michelle EchevarriaDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Arash NaghaviDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
G Daniel GrassDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Timothy J RobinsonDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Michael TomblynNavidea Biopharmaceuticals, Dublin, OH, USA.
Bijal ShahMalignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Julio ChavezMalignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Celeste BelloMalignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Ghassan El-HaddadDepartment of Interventional Radiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Louis HarrisonDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Sungjune KimDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Moffitt Cancer Center · USNavidea Biopharmaceuticals (United States) · US

Funding

Epigenetic Modulation of Immune Tolerance by Ionizing Radiation and ChemotherapyK08CA194273 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI KIM, SUNGJUNE · 2016 to 2020
$821k
NCI NIH HHS K08 CA194273
6 · The paper itself

Abstract

backgroundThe aim of this study was to evaluate the outcomes of priming salvage radioimmunotherapy (RIT) with a low dose of external beam radiotherapy (EBRT) in patients with relapsed low grade non-Hodgkin lymphoma (LG-NHL).

methodsPatients who received salvage RIT with or without 2 × 2 Gy EBRT between March 2009 and February 2013 were retrospectively reviewed at a single institution. Planning target volume (PTV) for EBRT was created by adding a 1-2 cm expansion to the gross tumor volume depending on the anatomical location. Kaplan-Meier method

resultsWe identified 22 patients who received salvage RIT without chemotherapy with a median follow up of 34 months. Of these, 9 (41%) patients were treated with EBRT immediately prior to RIT, and 13 (59%) received salvage RIT alone. Median FFP was not reached in patients who underwent combination treatment, while it was 9 months for patients treated with RIT alone (

conclusionsRIT outcomes and effects were improved with addition of low-dose EBRT immediately prior to it, in the treatment of relapsed LG-NHL with no additional toxicity. This study is hypothesis-generating and the findings should be validated in prospective studies.

Indexed as

CD20non-Hodgkin lymphomaradioimmunotherapy

Identifiers

PMID28491264
PMCPMC5405899
OpenAlexW2589142977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.